Biodesix Statistics
Total Valuation
Biodesix has a market cap or net worth of $93.82 million. The enterprise value is $132.58 million.
Important Dates
The last earnings date was Monday, March 3, 2025, after market close.
| Earnings Date | Mar 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Biodesix has 145.98 million shares outstanding. The number of shares has increased by 57.92% in one year.
| Current Share Class | 145.98M |
| Shares Outstanding | 145.98M |
| Shares Change (YoY) | +57.92% |
| Shares Change (QoQ) | +0.21% |
| Owned by Insiders (%) | 47.60% |
| Owned by Institutions (%) | 34.91% |
| Float | 66.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.22 |
| Forward PS | 1.02 |
| PB Ratio | 4.67 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.86 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.76, with a Debt / Equity ratio of 3.04.
| Current Ratio | 2.76 |
| Quick Ratio | 2.43 |
| Debt / Equity | 3.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.15 |
Financial Efficiency
Return on equity (ROE) is -337.30% and return on invested capital (ROIC) is -28.64%.
| Return on Equity (ROE) | -337.30% |
| Return on Assets (ROA) | -21.81% |
| Return on Invested Capital (ROIC) | -28.64% |
| Return on Capital Employed (ROCE) | -41.31% |
| Revenue Per Employee | $261,256 |
| Profits Per Employee | -$157,256 |
| Employee Count | 273 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 12.98 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -53.47% in the last 52 weeks. The beta is 1.10, so Biodesix's price volatility has been similar to the market average.
| Beta (5Y) | 1.10 |
| 52-Week Price Change | -53.47% |
| 50-Day Moving Average | 0.90 |
| 200-Day Moving Average | 1.41 |
| Relative Strength Index (RSI) | 32.80 |
| Average Volume (20 Days) | 550,592 |
Short Selling Information
The latest short interest is 1.26 million, so 0.86% of the outstanding shares have been sold short.
| Short Interest | 1.26M |
| Short Previous Month | 973,182 |
| Short % of Shares Out | 0.86% |
| Short % of Float | 1.90% |
| Short Ratio (days to cover) | 2.37 |
Income Statement
In the last 12 months, Biodesix had revenue of $71.32 million and -$42.93 million in losses. Loss per share was -$0.33.
| Revenue | 71.32M |
| Gross Profit | 55.75M |
| Operating Income | -34.26M |
| Pretax Income | n/a |
| Net Income | -42.93M |
| EBITDA | -28.49M |
| EBIT | -34.26M |
| Loss Per Share | -$0.33 |
Full Income StatementBalance Sheet
The company has $26.25 million in cash and $63.38 million in debt, giving a net cash position of -$37.14 million or -$0.25 per share.
| Cash & Cash Equivalents | 26.25M |
| Total Debt | 63.38M |
| Net Cash | -37.14M |
| Net Cash Per Share | -$0.25 |
| Equity (Book Value) | 20.88M |
| Book Value Per Share | 0.14 |
| Working Capital | 25.17M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$48.65 million and capital expenditures -$3.23 million, giving a free cash flow of -$51.88 million.
| Operating Cash Flow | -48.65M |
| Capital Expenditures | -3.23M |
| Free Cash Flow | -51.88M |
| FCF Per Share | -$0.36 |
Full Cash Flow StatementMargins
Gross margin is 78.17%, with operating and profit margins of -48.04% and -60.19%.
| Gross Margin | 78.17% |
| Operating Margin | -48.04% |
| Pretax Margin | -60.19% |
| Profit Margin | -60.19% |
| EBITDA Margin | -39.94% |
| EBIT Margin | -48.03% |
| FCF Margin | n/a |
Dividends & Yields
Biodesix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -57.92% |
| Shareholder Yield | -57.92% |
| Earnings Yield | -44.98% |
| FCF Yield | -54.36% |
Analyst Forecast
The average price target for Biodesix is $2.93, which is 355.89% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $2.93 |
| Price Target Difference | 355.89% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Biodesix has an Altman Z-Score of -5.2 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.2 |
| Piotroski F-Score | 3 |